Reviewing P3 Health Partners (NASDAQ:PIII) and MDxHealth (NASDAQ:MDXH)

P3 Health Partners (NASDAQ:PIII) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Profitability

This table compares P3 Health Partners and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-10.14%	-302.33%	-20.72%
MDxHealth	-31.07%	-1,078.01%	-21.71%

Institutional and Insider Ownership

7.8% of P3 Health Partners shares are held by institutional investors. 17.8% of P3 Health Partners shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

P3 Health Partners has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for P3 Health Partners and MDxHealth, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1	2	1	0	2.00
MDxHealth	1	0	4	0	2.60

P3 Health Partners presently has a consensus price target of $3.50, suggesting a potential upside of 34.62%. MDxHealth has a consensus price target of $7.75, suggesting a potential upside of 235.50%. Given MDxHealth’s stronger consensus rating and higher probable upside, analysts clearly believe MDxHealth is more favorable than P3 Health Partners.

Valuation & Earnings

This table compares P3 Health Partners and MDxHealth”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46 billion	0.01	-$147.95 million	($45.20)	-0.06
MDxHealth	$107.88 million	1.06	-$33.52 million	($0.67)	-3.45

MDxHealth has lower revenue, but higher earnings than P3 Health Partners. MDxHealth is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

About P3 Health Partners

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.